Compare GOOGL & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOOGL | NVO |
|---|---|---|
| Founded | 1998 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8T | 269.6B |
| IPO Year | 2015 | N/A |
| Metric | GOOGL | NVO |
|---|---|---|
| Price | $304.96 | $39.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 44 | 11 |
| Target Price | ★ $351.82 | $51.00 |
| AVG Volume (30 Days) | ★ 25.7M | 19.9M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | 0.28% | ★ 3.19% |
| EPS Growth | ★ 34.45 | N/A |
| EPS | ★ 10.81 | N/A |
| Revenue | ★ $402,836,000,000.00 | N/A |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $15.06 | $4.39 |
| P/E Ratio | $27.58 | ★ $13.60 |
| Revenue Growth | ★ 15.09 | N/A |
| 52 Week Low | $140.53 | $35.85 |
| 52 Week High | $349.00 | $82.23 |
| Indicator | GOOGL | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 35.79 |
| Support Level | $296.29 | N/A |
| Resistance Level | $319.52 | $50.30 |
| Average True Range (ATR) | 6.75 | 0.89 |
| MACD | -0.46 | 0.03 |
| Stochastic Oscillator | 40.19 | 28.36 |
Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV and YouTube Music, among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform accounts for roughly 10% of Alphabet's revenue. The firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.